Search

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Read more

SWG Preceptorship Program

Funding to enable an SWG create its own preceptorship—and promote learning and innovation in our community. The call for proposals is open until 12:00 CEST on March 28, 2025. Apply now.

Read more

6th European CAR T-cell Meeting

Dates: February 15-17, 2024
Location: Valencia, Spain
Format: Hybrid
Chairs: Michael Hudecek & Anna Sureda

Registration is closed. Those already registratered can view on-demand content via the platform until March 17.

Read more

EHA24 is YOUR congress – here’s how you can make the most of it

Congress season is an exciting time for any field. It’s a time when experts come together to share the latest developments, and also an opportunity to see friends and colleagues who you haven’t seen in a while.

Read more

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

Read more

EHA Diversity, Equity, and Inclusion Award 2024

The EHA Diversity, Equity, and Inclusion (DEI) Award celebrates achievements that foster inclusivity. It recognizes efforts taken by individuals, teams, or organizations (collectively “candidate”) to promote DEI within leadership, initiatives, and overall work.

Read more

EHA-HKSH Hematology Tutorial

EHA is joining the Hong Kong Society of Hematology (HKSH) to organize the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more